Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cancer Vaccines | 34 | 2023 | 1037 | 7.430 |
Why?
|
Dendritic Cells | 43 | 2023 | 2722 | 3.980 |
Why?
|
Multiple Myeloma | 50 | 2024 | 5146 | 3.940 |
Why?
|
Mucin-1 | 21 | 2017 | 538 | 3.870 |
Why?
|
Immunotherapy | 22 | 2023 | 4642 | 2.100 |
Why?
|
Hematologic Neoplasms | 15 | 2024 | 1896 | 1.990 |
Why?
|
Hematopoietic Stem Cell Transplantation | 32 | 2024 | 5672 | 1.570 |
Why?
|
Leukemia, Myeloid, Acute | 15 | 2022 | 3612 | 1.470 |
Why?
|
Immunotherapy, Active | 3 | 2018 | 58 | 1.450 |
Why?
|
Immunotherapy, Adoptive | 14 | 2023 | 1467 | 1.240 |
Why?
|
Azacitidine | 3 | 2019 | 335 | 1.100 |
Why?
|
Cell Fusion | 12 | 2012 | 294 | 0.930 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 2 | 2017 | 212 | 0.910 |
Why?
|
Vaccination | 13 | 2023 | 3370 | 0.880 |
Why?
|
Graft vs Host Disease | 16 | 2024 | 3028 | 0.850 |
Why?
|
Antigens, Neoplasm | 8 | 2021 | 1985 | 0.830 |
Why?
|
T-Lymphocytes | 19 | 2021 | 10175 | 0.820 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 22 | 2024 | 11736 | 0.720 |
Why?
|
Thalidomide | 5 | 2017 | 885 | 0.720 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 8 | 2023 | 888 | 0.690 |
Why?
|
Tumor Microenvironment | 9 | 2023 | 3868 | 0.670 |
Why?
|
Dexamethasone | 6 | 2024 | 1947 | 0.670 |
Why?
|
Lymphocyte Activation | 19 | 2022 | 5463 | 0.660 |
Why?
|
Stem Cell Transplantation | 9 | 2018 | 1600 | 0.660 |
Why?
|
Immunomodulation | 4 | 2018 | 548 | 0.650 |
Why?
|
Antibodies, Monoclonal | 14 | 2024 | 9172 | 0.630 |
Why?
|
Cell Proliferation | 17 | 2020 | 10432 | 0.630 |
Why?
|
Transplantation Conditioning | 7 | 2020 | 1590 | 0.620 |
Why?
|
Transplantation, Autologous | 13 | 2023 | 2112 | 0.610 |
Why?
|
Transplantation, Homologous | 12 | 2024 | 4804 | 0.590 |
Why?
|
T-Lymphocytes, Regulatory | 10 | 2017 | 3077 | 0.590 |
Why?
|
Interleukin-12 | 4 | 2008 | 577 | 0.560 |
Why?
|
Remission Induction | 9 | 2017 | 2391 | 0.550 |
Why?
|
Gene Expression Regulation, Leukemic | 2 | 2017 | 651 | 0.540 |
Why?
|
Peptides | 6 | 2017 | 4354 | 0.510 |
Why?
|
Melphalan | 5 | 2019 | 420 | 0.490 |
Why?
|
Cord Blood Stem Cell Transplantation | 4 | 2019 | 305 | 0.480 |
Why?
|
Immunity, Cellular | 5 | 2019 | 1550 | 0.470 |
Why?
|
Immune Tolerance | 4 | 2018 | 2299 | 0.460 |
Why?
|
Antibodies, Neoplasm | 1 | 2015 | 280 | 0.460 |
Why?
|
Lymphoma, B-Cell | 4 | 2021 | 938 | 0.450 |
Why?
|
Cell Communication | 4 | 2017 | 1654 | 0.440 |
Why?
|
Molecular Targeted Therapy | 5 | 2018 | 2812 | 0.430 |
Why?
|
Humans | 154 | 2024 | 760617 | 0.420 |
Why?
|
Antigens, CD34 | 6 | 2024 | 658 | 0.410 |
Why?
|
Antigen Presentation | 7 | 2012 | 1250 | 0.410 |
Why?
|
Apoptosis | 11 | 2020 | 9476 | 0.410 |
Why?
|
Coculture Techniques | 7 | 2017 | 1336 | 0.400 |
Why?
|
Recurrence | 12 | 2023 | 8426 | 0.400 |
Why?
|
Lymphocyte Transfusion | 2 | 2014 | 232 | 0.400 |
Why?
|
Bone Marrow | 3 | 2023 | 2909 | 0.400 |
Why?
|
Oligonucleotides | 2 | 2020 | 566 | 0.390 |
Why?
|
CD8-Positive T-Lymphocytes | 5 | 2022 | 4571 | 0.380 |
Why?
|
T-Lymphocytes, Cytotoxic | 5 | 2012 | 1779 | 0.370 |
Why?
|
MicroRNAs | 5 | 2020 | 3805 | 0.370 |
Why?
|
Stromal Cells | 1 | 2017 | 1329 | 0.370 |
Why?
|
Cell Line, Tumor | 18 | 2020 | 16967 | 0.370 |
Why?
|
Carcinoembryonic Antigen | 1 | 2012 | 335 | 0.370 |
Why?
|
Antigens, CD | 5 | 2016 | 3998 | 0.370 |
Why?
|
Apoptosis Regulatory Proteins | 3 | 2015 | 1134 | 0.360 |
Why?
|
Granulocyte Colony-Stimulating Factor | 4 | 2007 | 629 | 0.360 |
Why?
|
Leukocytes, Mononuclear | 4 | 2017 | 1835 | 0.340 |
Why?
|
Oxidative Stress | 3 | 2017 | 3113 | 0.330 |
Why?
|
Cytotoxicity, Immunologic | 7 | 2017 | 1349 | 0.310 |
Why?
|
Granzymes | 1 | 2010 | 277 | 0.310 |
Why?
|
Antineoplastic Agents | 13 | 2017 | 13635 | 0.300 |
Why?
|
Reactive Oxygen Species | 6 | 2017 | 2137 | 0.300 |
Why?
|
Virus Activation | 3 | 2019 | 320 | 0.300 |
Why?
|
Animals | 33 | 2022 | 168201 | 0.290 |
Why?
|
Neoplastic Stem Cells | 2 | 2013 | 1350 | 0.290 |
Why?
|
Interferon-gamma | 6 | 2017 | 3145 | 0.280 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 4 | 2020 | 1405 | 0.280 |
Why?
|
Antigens, Differentiation | 1 | 2010 | 908 | 0.280 |
Why?
|
Kidney Neoplasms | 5 | 2007 | 4250 | 0.280 |
Why?
|
Transplantation Immunology | 3 | 2016 | 532 | 0.270 |
Why?
|
Immunologic Factors | 3 | 2018 | 1589 | 0.270 |
Why?
|
Hematopoietic Stem Cell Mobilization | 3 | 2007 | 225 | 0.260 |
Why?
|
Killer Cells, Natural | 6 | 2016 | 2191 | 0.260 |
Why?
|
Th17 Cells | 1 | 2012 | 793 | 0.260 |
Why?
|
Flow Cytometry | 10 | 2015 | 5863 | 0.260 |
Why?
|
Tumor Cells, Cultured | 12 | 2019 | 6126 | 0.250 |
Why?
|
Breast Neoplasms | 14 | 2017 | 20988 | 0.250 |
Why?
|
Immunophenotyping | 10 | 2013 | 1865 | 0.250 |
Why?
|
Leukemia | 4 | 2016 | 1520 | 0.250 |
Why?
|
Neoplasms | 8 | 2016 | 22131 | 0.240 |
Why?
|
Pancreatic Neoplasms | 1 | 2022 | 5367 | 0.230 |
Why?
|
Anilides | 2 | 2017 | 411 | 0.230 |
Why?
|
Boronic Acids | 4 | 2014 | 915 | 0.220 |
Why?
|
B-Cell Maturation Antigen | 2 | 2022 | 149 | 0.220 |
Why?
|
Gene Expression Regulation, Neoplastic | 8 | 2020 | 8542 | 0.210 |
Why?
|
Mice | 21 | 2022 | 81368 | 0.210 |
Why?
|
Signal Transduction | 6 | 2017 | 23416 | 0.210 |
Why?
|
Drug Synergism | 6 | 2017 | 1755 | 0.210 |
Why?
|
Immunoenzyme Techniques | 3 | 2015 | 1703 | 0.210 |
Why?
|
Carcinoma, Renal Cell | 3 | 2007 | 3164 | 0.210 |
Why?
|
Whole-Body Irradiation | 2 | 2020 | 432 | 0.200 |
Why?
|
Th1-Th2 Balance | 2 | 2012 | 38 | 0.200 |
Why?
|
Leukoencephalopathy, Progressive Multifocal | 2 | 2014 | 133 | 0.200 |
Why?
|
Pyrazines | 4 | 2014 | 1202 | 0.200 |
Why?
|
fms-Like Tyrosine Kinase 3 | 2 | 2017 | 495 | 0.200 |
Why?
|
Immune System | 2 | 2018 | 791 | 0.200 |
Why?
|
Membrane Glycoproteins | 1 | 2012 | 3688 | 0.190 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 4 | 2015 | 693 | 0.190 |
Why?
|
Down-Regulation | 3 | 2019 | 2915 | 0.190 |
Why?
|
Cryptosporidiosis | 1 | 2021 | 52 | 0.190 |
Why?
|
Mice, SCID | 3 | 2016 | 2625 | 0.180 |
Why?
|
Hodgkin Disease | 3 | 2019 | 1378 | 0.180 |
Why?
|
Proto-Oncogene Proteins c-myc | 2 | 2017 | 988 | 0.180 |
Why?
|
Oncogene Proteins | 2 | 2016 | 718 | 0.180 |
Why?
|
Cell Differentiation | 10 | 2017 | 11514 | 0.180 |
Why?
|
Lymphoma, Non-Hodgkin | 3 | 2022 | 1372 | 0.170 |
Why?
|
Photopheresis | 1 | 2020 | 35 | 0.170 |
Why?
|
Xenograft Model Antitumor Assays | 3 | 2020 | 3599 | 0.170 |
Why?
|
Oligopeptides | 2 | 2024 | 1185 | 0.170 |
Why?
|
Biomedical Research | 3 | 2010 | 3426 | 0.170 |
Why?
|
Mice, Inbred NOD | 2 | 2015 | 1827 | 0.170 |
Why?
|
Vitamin D | 2 | 2012 | 3302 | 0.170 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2010 | 687 | 0.170 |
Why?
|
Blotting, Western | 4 | 2015 | 5034 | 0.170 |
Why?
|
Middle Aged | 51 | 2024 | 220584 | 0.170 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 4570 | 0.170 |
Why?
|
Neoplasm, Residual | 3 | 2024 | 1008 | 0.170 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2021 | 326 | 0.160 |
Why?
|
Hematopoietic Stem Cells | 6 | 2013 | 3394 | 0.160 |
Why?
|
Female | 60 | 2024 | 392148 | 0.160 |
Why?
|
Isoantigens | 2 | 2017 | 551 | 0.160 |
Why?
|
Lymphocyte Culture Test, Mixed | 6 | 2009 | 508 | 0.160 |
Why?
|
Neurotoxicity Syndromes | 1 | 2023 | 301 | 0.160 |
Why?
|
Cytarabine | 3 | 2019 | 697 | 0.150 |
Why?
|
Interleukin-2 | 3 | 2016 | 1887 | 0.150 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2021 | 629 | 0.150 |
Why?
|
Oligonucleotides, Antisense | 1 | 2020 | 458 | 0.150 |
Why?
|
Oxidation-Reduction | 4 | 2017 | 2231 | 0.150 |
Why?
|
Aged | 36 | 2024 | 169042 | 0.150 |
Why?
|
Vinblastine | 1 | 2019 | 488 | 0.150 |
Why?
|
Lymphoma | 5 | 2020 | 1899 | 0.150 |
Why?
|
Herpesvirus 6, Human | 1 | 2018 | 96 | 0.150 |
Why?
|
Azepines | 1 | 2019 | 329 | 0.150 |
Why?
|
Forkhead Transcription Factors | 4 | 2017 | 1614 | 0.150 |
Why?
|
Cross-Priming | 1 | 2017 | 76 | 0.140 |
Why?
|
Epstein-Barr Virus Nuclear Antigens | 1 | 2018 | 157 | 0.140 |
Why?
|
Drug Resistance, Neoplasm | 7 | 2017 | 5304 | 0.140 |
Why?
|
Perforin | 1 | 2017 | 166 | 0.140 |
Why?
|
Leukemia, Promyelocytic, Acute | 1 | 2019 | 251 | 0.140 |
Why?
|
Glutathione | 3 | 2015 | 582 | 0.140 |
Why?
|
Adult | 45 | 2024 | 220969 | 0.140 |
Why?
|
Myelodysplastic Syndromes | 2 | 2020 | 1394 | 0.140 |
Why?
|
Male | 50 | 2024 | 360358 | 0.140 |
Why?
|
Fusion Proteins, bcr-abl | 2 | 2010 | 431 | 0.140 |
Why?
|
Receptors, CCR7 | 2 | 2008 | 107 | 0.140 |
Why?
|
Galactosylceramides | 1 | 2017 | 92 | 0.140 |
Why?
|
JC Virus | 2 | 2014 | 87 | 0.140 |
Why?
|
Mitoxantrone | 3 | 2017 | 148 | 0.140 |
Why?
|
Proto-Oncogene Proteins c-jun | 1 | 2017 | 287 | 0.130 |
Why?
|
Retroviridae | 1 | 2019 | 851 | 0.130 |
Why?
|
Enterocolitis, Pseudomembranous | 1 | 1998 | 264 | 0.130 |
Why?
|
Dacarbazine | 1 | 2019 | 559 | 0.130 |
Why?
|
Phosphoric Monoester Hydrolases | 2 | 2015 | 412 | 0.130 |
Why?
|
Tretinoin | 1 | 2019 | 519 | 0.130 |
Why?
|
HMGB1 Protein | 1 | 2017 | 136 | 0.130 |
Why?
|
Skin Neoplasms | 1 | 2015 | 5812 | 0.130 |
Why?
|
Bone Marrow Transplantation | 3 | 2017 | 2690 | 0.130 |
Why?
|
Polydeoxyribonucleotides | 2 | 2010 | 136 | 0.130 |
Why?
|
Cell Survival | 5 | 2016 | 5780 | 0.130 |
Why?
|
Glioblastoma | 2 | 2023 | 3481 | 0.130 |
Why?
|
Blood Specimen Collection | 1 | 2016 | 238 | 0.120 |
Why?
|
Doxorubicin | 4 | 2019 | 2224 | 0.120 |
Why?
|
Pyridines | 2 | 2017 | 2874 | 0.120 |
Why?
|
Ribonuclease III | 1 | 2017 | 279 | 0.120 |
Why?
|
Etoposide | 3 | 2017 | 634 | 0.120 |
Why?
|
Neoplasm Transplantation | 1 | 2019 | 2010 | 0.120 |
Why?
|
Chemokine CXCL12 | 1 | 2017 | 454 | 0.120 |
Why?
|
Tumor Escape | 1 | 2018 | 371 | 0.120 |
Why?
|
Gene Silencing | 3 | 2017 | 1503 | 0.120 |
Why?
|
Immunoblotting | 3 | 2014 | 1646 | 0.120 |
Why?
|
Hybrid Cells | 2 | 2005 | 422 | 0.120 |
Why?
|
Hepatic Veno-Occlusive Disease | 2 | 2010 | 220 | 0.120 |
Why?
|
Virus Diseases | 1 | 2001 | 718 | 0.120 |
Why?
|
Antigen-Presenting Cells | 1 | 2018 | 963 | 0.120 |
Why?
|
Response Elements | 1 | 2016 | 309 | 0.120 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2015 | 2872 | 0.120 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 2016 | 535 | 0.120 |
Why?
|
NADP | 1 | 2015 | 227 | 0.110 |
Why?
|
Graft vs Leukemia Effect | 1 | 2014 | 121 | 0.110 |
Why?
|
Yttrium Radioisotopes | 1 | 2015 | 107 | 0.110 |
Why?
|
Transplantation | 1 | 2015 | 219 | 0.110 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 2 | 2012 | 306 | 0.110 |
Why?
|
Fetal Blood | 2 | 2019 | 1347 | 0.110 |
Why?
|
Treatment Outcome | 19 | 2024 | 64568 | 0.110 |
Why?
|
Lymphoma, T-Cell | 1 | 2016 | 304 | 0.110 |
Why?
|
Leukapheresis | 3 | 2003 | 134 | 0.110 |
Why?
|
Cells, Cultured | 7 | 2014 | 18937 | 0.110 |
Why?
|
Janus Kinase 2 | 1 | 2017 | 560 | 0.110 |
Why?
|
Antigens, CD1 | 3 | 2008 | 439 | 0.110 |
Why?
|
Interleukin-10 | 3 | 2009 | 1172 | 0.110 |
Why?
|
Necrosis | 2 | 2015 | 1610 | 0.110 |
Why?
|
Parathyroid Hormone | 2 | 2012 | 1803 | 0.110 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2018 | 774 | 0.110 |
Why?
|
Fowlpox virus | 1 | 2012 | 21 | 0.110 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2019 | 937 | 0.100 |
Why?
|
PPAR delta | 1 | 2012 | 40 | 0.100 |
Why?
|
Herpesvirus 4, Human | 1 | 2018 | 1077 | 0.100 |
Why?
|
STAT3 Transcription Factor | 1 | 2017 | 871 | 0.100 |
Why?
|
Bacterial Infections | 1 | 2001 | 1389 | 0.100 |
Why?
|
Arabinonucleosides | 1 | 2012 | 34 | 0.100 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 3 | 2003 | 263 | 0.100 |
Why?
|
Adenine Nucleotides | 1 | 2012 | 111 | 0.100 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2013 | 296 | 0.100 |
Why?
|
T-Lymphocyte Subsets | 3 | 2012 | 1798 | 0.100 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2018 | 612 | 0.100 |
Why?
|
STAT Transcription Factors | 1 | 2012 | 188 | 0.100 |
Why?
|
Ifosfamide | 2 | 2003 | 232 | 0.100 |
Why?
|
Interleukin-4 | 3 | 2014 | 1146 | 0.100 |
Why?
|
Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2012 | 152 | 0.100 |
Why?
|
Combined Modality Therapy | 6 | 2016 | 8516 | 0.090 |
Why?
|
Receptors, Antigen, T-Cell | 2 | 2021 | 2546 | 0.090 |
Why?
|
Hematologic Diseases | 2 | 2012 | 496 | 0.090 |
Why?
|
PTEN Phosphohydrolase | 1 | 2017 | 1113 | 0.090 |
Why?
|
Transcriptional Activation | 1 | 2017 | 1755 | 0.090 |
Why?
|
Viral Proteins | 1 | 2018 | 1799 | 0.090 |
Why?
|
Deglutition Disorders | 1 | 2017 | 626 | 0.090 |
Why?
|
RNA, Messenger | 3 | 2015 | 12758 | 0.090 |
Why?
|
Lymphocyte Depletion | 2 | 2006 | 602 | 0.090 |
Why?
|
Cytokines | 3 | 2017 | 7373 | 0.090 |
Why?
|
Tumor Suppressor Proteins | 2 | 2012 | 2801 | 0.090 |
Why?
|
Genes, T-Cell Receptor beta | 1 | 2010 | 70 | 0.090 |
Why?
|
Pyrimidines | 2 | 2019 | 3027 | 0.090 |
Why?
|
Radiotherapy | 1 | 2017 | 1497 | 0.090 |
Why?
|
Survival Analysis | 7 | 2019 | 10073 | 0.080 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 2011 | 355 | 0.080 |
Why?
|
Mitogens | 1 | 2010 | 229 | 0.080 |
Why?
|
Sirolimus | 1 | 2017 | 1533 | 0.080 |
Why?
|
Chromosome Aberrations | 1 | 2016 | 1768 | 0.080 |
Why?
|
Transduction, Genetic | 1 | 2012 | 901 | 0.080 |
Why?
|
Antibodies, Protozoan | 1 | 2010 | 251 | 0.080 |
Why?
|
Radiation Injuries | 1 | 2017 | 1189 | 0.080 |
Why?
|
Multiple Organ Failure | 2 | 2010 | 387 | 0.080 |
Why?
|
Brain Neoplasms | 2 | 2023 | 9026 | 0.080 |
Why?
|
Maximum Tolerated Dose | 3 | 2017 | 883 | 0.080 |
Why?
|
Antigens, Protozoan | 1 | 2010 | 316 | 0.080 |
Why?
|
Cell Division | 3 | 2012 | 4457 | 0.080 |
Why?
|
Mice, Inbred C57BL | 5 | 2019 | 22115 | 0.080 |
Why?
|
Up-Regulation | 1 | 2017 | 4117 | 0.080 |
Why?
|
Cell Separation | 3 | 2016 | 1718 | 0.070 |
Why?
|
Metabolic Networks and Pathways | 1 | 2012 | 789 | 0.070 |
Why?
|
Survival Rate | 8 | 2015 | 12719 | 0.070 |
Why?
|
Cytotoxicity Tests, Immunologic | 2 | 2005 | 317 | 0.070 |
Why?
|
Receptors, Immunologic | 1 | 2014 | 1409 | 0.070 |
Why?
|
DNA Methylation | 2 | 2019 | 4391 | 0.070 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2022 | 9277 | 0.070 |
Why?
|
CD4-Positive T-Lymphocytes | 3 | 2012 | 4366 | 0.070 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2013 | 2509 | 0.070 |
Why?
|
Fibrinolytic Agents | 2 | 2010 | 2073 | 0.070 |
Why?
|
Disease-Free Survival | 7 | 2015 | 6807 | 0.070 |
Why?
|
Isocoumarins | 1 | 2006 | 21 | 0.070 |
Why?
|
Authorship | 1 | 2010 | 284 | 0.070 |
Why?
|
Antimitotic Agents | 1 | 2006 | 28 | 0.070 |
Why?
|
Cell Polarity | 1 | 2010 | 635 | 0.070 |
Why?
|
Disease Models, Animal | 3 | 2019 | 18221 | 0.070 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2017 | 2917 | 0.070 |
Why?
|
Clone Cells | 1 | 2010 | 1657 | 0.070 |
Why?
|
Filgrastim | 2 | 2007 | 132 | 0.060 |
Why?
|
Nuclear Proteins | 2 | 2012 | 5789 | 0.060 |
Why?
|
Immunocompromised Host | 2 | 2021 | 858 | 0.060 |
Why?
|
Young Adult | 12 | 2024 | 59179 | 0.060 |
Why?
|
Chronic Disease | 5 | 2023 | 9311 | 0.060 |
Why?
|
Immunosuppressive Agents | 1 | 2018 | 4174 | 0.060 |
Why?
|
Granulocyte Precursor Cells | 1 | 2004 | 49 | 0.060 |
Why?
|
Bone Marrow Cells | 3 | 2004 | 2409 | 0.060 |
Why?
|
Conflict of Interest | 1 | 2010 | 553 | 0.060 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2016 | 1639 | 0.060 |
Why?
|
Lymphocyte Count | 3 | 2016 | 778 | 0.060 |
Why?
|
Fatty Acids | 1 | 2012 | 1808 | 0.060 |
Why?
|
Interleukin-7 | 1 | 2005 | 143 | 0.060 |
Why?
|
Tissue Donors | 3 | 2018 | 2331 | 0.060 |
Why?
|
Protein Kinase Inhibitors | 2 | 2017 | 5672 | 0.060 |
Why?
|
Gene Expression | 1 | 2017 | 7568 | 0.060 |
Why?
|
Disclosure | 1 | 2010 | 747 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2021 | 10199 | 0.060 |
Why?
|
Interleukin-6 | 1 | 2014 | 3206 | 0.060 |
Why?
|
Neoplasms, Experimental | 2 | 2019 | 1226 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 2 | 2020 | 6474 | 0.060 |
Why?
|
Aged, 80 and over | 9 | 2021 | 58894 | 0.060 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2013 | 2821 | 0.050 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2009 | 709 | 0.050 |
Why?
|
Drug Industry | 1 | 2010 | 788 | 0.050 |
Why?
|
Clinical Trials as Topic | 4 | 2014 | 7995 | 0.050 |
Why?
|
Case-Control Studies | 4 | 2015 | 22148 | 0.050 |
Why?
|
Antibody Formation | 2 | 2005 | 1390 | 0.050 |
Why?
|
Th1 Cells | 1 | 2008 | 1027 | 0.050 |
Why?
|
Genetic Vectors | 1 | 2012 | 3392 | 0.050 |
Why?
|
Glucocorticoids | 4 | 2018 | 2160 | 0.050 |
Why?
|
Drug Administration Schedule | 5 | 2013 | 4845 | 0.050 |
Why?
|
Receptors, Chemokine | 1 | 2005 | 652 | 0.050 |
Why?
|
Sterilization | 1 | 2003 | 132 | 0.050 |
Why?
|
Transcription, Genetic | 1 | 2016 | 7583 | 0.050 |
Why?
|
Lymphocytes | 2 | 2023 | 2604 | 0.050 |
Why?
|
Pneumococcal Vaccines | 1 | 2005 | 397 | 0.050 |
Why?
|
Mitosis | 1 | 2006 | 1187 | 0.050 |
Why?
|
Pentostatin | 1 | 2020 | 26 | 0.050 |
Why?
|
K562 Cells | 3 | 2010 | 641 | 0.050 |
Why?
|
Proto-Oncogene Proteins | 1 | 2013 | 4512 | 0.050 |
Why?
|
Transcription Factors | 2 | 2012 | 12116 | 0.050 |
Why?
|
Mice, Inbred BALB C | 4 | 2013 | 6188 | 0.040 |
Why?
|
Phytohemagglutinins | 1 | 2000 | 165 | 0.040 |
Why?
|
CD4-CD8 Ratio | 1 | 2000 | 114 | 0.040 |
Why?
|
Pancreatitis | 1 | 2007 | 1097 | 0.040 |
Why?
|
Kidney Diseases | 1 | 2011 | 2090 | 0.040 |
Why?
|
Antibodies | 1 | 2008 | 2414 | 0.040 |
Why?
|
Idarubicin | 1 | 2019 | 59 | 0.040 |
Why?
|
Salvage Therapy | 2 | 2017 | 1263 | 0.040 |
Why?
|
Immunization, Passive | 1 | 2002 | 616 | 0.040 |
Why?
|
Hypersensitivity, Delayed | 1 | 2000 | 490 | 0.040 |
Why?
|
Follow-Up Studies | 6 | 2022 | 39063 | 0.040 |
Why?
|
Prednisone | 2 | 2018 | 1562 | 0.040 |
Why?
|
U937 Cells | 1 | 2019 | 261 | 0.040 |
Why?
|
Foscarnet | 1 | 2018 | 35 | 0.040 |
Why?
|
Antigens, CD19 | 1 | 2021 | 424 | 0.040 |
Why?
|
Periodicals as Topic | 1 | 2010 | 1463 | 0.040 |
Why?
|
Fluorescent Antibody Technique | 2 | 2013 | 2467 | 0.040 |
Why?
|
Bacterial Vaccines | 1 | 2001 | 399 | 0.040 |
Why?
|
Mice, Transgenic | 3 | 2019 | 9529 | 0.040 |
Why?
|
Lectins, C-Type | 1 | 2001 | 584 | 0.040 |
Why?
|
Vidarabine | 1 | 2019 | 336 | 0.040 |
Why?
|
Skin Tests | 1 | 2000 | 637 | 0.040 |
Why?
|
Steroids | 1 | 2023 | 929 | 0.040 |
Why?
|
Contrast Media | 1 | 2011 | 5305 | 0.040 |
Why?
|
Cyclosporine | 1 | 2020 | 778 | 0.040 |
Why?
|
Models, Biological | 2 | 2012 | 9461 | 0.040 |
Why?
|
Treatment Failure | 2 | 2020 | 2635 | 0.040 |
Why?
|
Thrombopoietin | 1 | 2019 | 226 | 0.040 |
Why?
|
Chimerism | 1 | 2018 | 155 | 0.040 |
Why?
|
Confidence Intervals | 1 | 2003 | 2925 | 0.030 |
Why?
|
Herpesvirus 8, Human | 1 | 1999 | 255 | 0.030 |
Why?
|
Methotrexate | 2 | 2020 | 1716 | 0.030 |
Why?
|
Immunoglobulins | 1 | 2000 | 850 | 0.030 |
Why?
|
Heartburn | 1 | 2017 | 70 | 0.030 |
Why?
|
Tacrolimus | 1 | 2020 | 733 | 0.030 |
Why?
|
Glutamate-Cysteine Ligase | 1 | 2016 | 23 | 0.030 |
Why?
|
Mutation | 2 | 2019 | 30016 | 0.030 |
Why?
|
Th2 Cells | 1 | 2001 | 1056 | 0.030 |
Why?
|
NF-kappa B p50 Subunit | 1 | 2016 | 103 | 0.030 |
Why?
|
Recombinant Proteins | 2 | 2007 | 6520 | 0.030 |
Why?
|
Cyclin D2 | 1 | 2016 | 98 | 0.030 |
Why?
|
Benzylamines | 1 | 2017 | 246 | 0.030 |
Why?
|
Protein Binding | 1 | 2008 | 9345 | 0.030 |
Why?
|
DNA-Binding Proteins | 1 | 2013 | 9586 | 0.030 |
Why?
|
Recombinant Fusion Proteins | 1 | 2004 | 3730 | 0.030 |
Why?
|
Heterocyclic Compounds | 1 | 2017 | 245 | 0.030 |
Why?
|
Phenotype | 3 | 2011 | 16571 | 0.030 |
Why?
|
Mediastinum | 1 | 2017 | 266 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2011 | 10754 | 0.030 |
Why?
|
Autoimmune Diseases | 1 | 2007 | 2238 | 0.030 |
Why?
|
Viral Vaccines | 1 | 2001 | 595 | 0.030 |
Why?
|
Endpoint Determination | 1 | 2018 | 590 | 0.030 |
Why?
|
Ikaros Transcription Factor | 1 | 2017 | 232 | 0.030 |
Why?
|
Transcription Factor RelA | 1 | 2016 | 254 | 0.030 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 2016 | 302 | 0.030 |
Why?
|
Radioimmunotherapy | 1 | 2015 | 91 | 0.030 |
Why?
|
Computational Biology | 2 | 2017 | 3509 | 0.030 |
Why?
|
Fatigue | 2 | 2013 | 1550 | 0.030 |
Why?
|
Mycosis Fungoides | 1 | 2016 | 170 | 0.030 |
Why?
|
Retreatment | 1 | 2016 | 596 | 0.030 |
Why?
|
Quality of Life | 1 | 2016 | 13347 | 0.030 |
Why?
|
Staphylococcus aureus | 1 | 2003 | 1457 | 0.030 |
Why?
|
Diarrhea | 1 | 2021 | 1317 | 0.030 |
Why?
|
Antigens, CD1d | 2 | 2008 | 228 | 0.030 |
Why?
|
Immunity | 1 | 2000 | 994 | 0.030 |
Why?
|
Amino Acid Sequence | 3 | 2011 | 13441 | 0.030 |
Why?
|
Prostatic Neoplasms | 1 | 2017 | 11106 | 0.030 |
Why?
|
Neutrophils | 2 | 2017 | 3763 | 0.030 |
Why?
|
Acute Disease | 2 | 2017 | 7237 | 0.030 |
Why?
|
Cohort Studies | 5 | 2019 | 41457 | 0.030 |
Why?
|
Natural Killer T-Cells | 1 | 2017 | 322 | 0.030 |
Why?
|
Pulmonary Heart Disease | 1 | 1993 | 34 | 0.030 |
Why?
|
Carcinoma | 2 | 2002 | 2327 | 0.030 |
Why?
|
Mice, Nude | 2 | 2010 | 3605 | 0.030 |
Why?
|
Immunohistochemistry | 2 | 2004 | 11069 | 0.030 |
Why?
|
Chile | 1 | 2013 | 256 | 0.030 |
Why?
|
United States | 3 | 2021 | 72272 | 0.030 |
Why?
|
Histocompatibility Testing | 1 | 2014 | 712 | 0.030 |
Why?
|
Time Factors | 5 | 2017 | 39913 | 0.030 |
Why?
|
Colony-Forming Units Assay | 1 | 2012 | 351 | 0.030 |
Why?
|
Epoxy Compounds | 1 | 2012 | 137 | 0.020 |
Why?
|
Genes, Tumor Suppressor | 1 | 2016 | 1056 | 0.020 |
Why?
|
Proton Pump Inhibitors | 1 | 2017 | 530 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 2 | 2015 | 20556 | 0.020 |
Why?
|
Luciferases | 1 | 2013 | 712 | 0.020 |
Why?
|
Cadherins | 1 | 2016 | 901 | 0.020 |
Why?
|
Cryopreservation | 1 | 2016 | 728 | 0.020 |
Why?
|
Retrospective Studies | 5 | 2024 | 80566 | 0.020 |
Why?
|
Israel | 1 | 2013 | 716 | 0.020 |
Why?
|
Triiodobenzoic Acids | 1 | 2011 | 123 | 0.020 |
Why?
|
Dioxygenases | 1 | 2013 | 344 | 0.020 |
Why?
|
Cell Culture Techniques | 3 | 2004 | 1662 | 0.020 |
Why?
|
Drug Resistance | 2 | 2011 | 1594 | 0.020 |
Why?
|
Telomerase | 1 | 2016 | 744 | 0.020 |
Why?
|
beta Catenin | 1 | 2016 | 1039 | 0.020 |
Why?
|
Consensus | 1 | 2020 | 3117 | 0.020 |
Why?
|
Protein Subunits | 1 | 2014 | 942 | 0.020 |
Why?
|
Adolescent | 7 | 2024 | 88234 | 0.020 |
Why?
|
Adenine | 1 | 2016 | 985 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2016 | 2567 | 0.020 |
Why?
|
Myeloproliferative Disorders | 1 | 2016 | 611 | 0.020 |
Why?
|
Immunoprecipitation | 1 | 2012 | 876 | 0.020 |
Why?
|
Observation | 1 | 2011 | 310 | 0.020 |
Why?
|
Glucocorticoid-Induced TNFR-Related Protein | 1 | 2009 | 39 | 0.020 |
Why?
|
Acetylcysteine | 1 | 2011 | 260 | 0.020 |
Why?
|
Myelopoiesis | 1 | 2010 | 134 | 0.020 |
Why?
|
Paclitaxel | 3 | 2002 | 1730 | 0.020 |
Why?
|
Prognosis | 3 | 2018 | 29600 | 0.020 |
Why?
|
Pilot Projects | 1 | 2022 | 8618 | 0.020 |
Why?
|
Sensation Disorders | 1 | 2010 | 160 | 0.020 |
Why?
|
Viral Load | 1 | 2018 | 3325 | 0.020 |
Why?
|
Prospective Studies | 3 | 2023 | 54360 | 0.020 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2012 | 662 | 0.020 |
Why?
|
Receptors, Nerve Growth Factor | 1 | 2009 | 198 | 0.020 |
Why?
|
Biopolymers | 1 | 2009 | 183 | 0.020 |
Why?
|
Lymphocyte Subsets | 1 | 2009 | 310 | 0.020 |
Why?
|
Neutropenia | 1 | 2013 | 885 | 0.020 |
Why?
|
Polyneuropathies | 1 | 2009 | 137 | 0.020 |
Why?
|
Arsenicals | 1 | 2008 | 118 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2013 | 3591 | 0.020 |
Why?
|
Placebos | 1 | 2012 | 1667 | 0.020 |
Why?
|
Leukocyte Count | 1 | 2011 | 1597 | 0.020 |
Why?
|
Angiogenesis Inhibitors | 1 | 2017 | 2048 | 0.020 |
Why?
|
Piperidines | 1 | 2016 | 1655 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2016 | 3777 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2001 | 4745 | 0.020 |
Why?
|
Chromatin Immunoprecipitation | 1 | 2010 | 852 | 0.020 |
Why?
|
Erythrocytes | 1 | 2016 | 2410 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2016 | 3419 | 0.020 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2009 | 581 | 0.020 |
Why?
|
India | 1 | 2013 | 2286 | 0.020 |
Why?
|
T-Box Domain Proteins | 1 | 2009 | 469 | 0.020 |
Why?
|
Molecular Sequence Data | 2 | 2010 | 17629 | 0.020 |
Why?
|
Thrombocytopenia | 1 | 2015 | 1182 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2014 | 4341 | 0.020 |
Why?
|
Oxides | 1 | 2008 | 401 | 0.020 |
Why?
|
Graft vs Tumor Effect | 1 | 2006 | 68 | 0.020 |
Why?
|
ADP Ribose Transferases | 1 | 1986 | 90 | 0.020 |
Why?
|
Neoplastic Cells, Circulating | 1 | 1993 | 943 | 0.020 |
Why?
|
Exotoxins | 1 | 1986 | 121 | 0.020 |
Why?
|
HLA-DR Antigens | 2 | 1999 | 602 | 0.020 |
Why?
|
Pyrazoles | 1 | 2016 | 2008 | 0.020 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 1993 | 926 | 0.020 |
Why?
|
Protease Inhibitors | 1 | 2009 | 753 | 0.020 |
Why?
|
Protein Multimerization | 1 | 2010 | 982 | 0.020 |
Why?
|
Thiazoles | 1 | 2012 | 1517 | 0.020 |
Why?
|
RNA, Neoplasm | 1 | 2007 | 749 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2016 | 5780 | 0.020 |
Why?
|
Immunity, Innate | 1 | 2017 | 3045 | 0.010 |
Why?
|
Protein Transport | 1 | 2010 | 1966 | 0.010 |
Why?
|
Education, Medical, Continuing | 1 | 2010 | 823 | 0.010 |
Why?
|
Pneumonia | 1 | 2016 | 2143 | 0.010 |
Why?
|
Protein Structure, Tertiary | 1 | 2011 | 3792 | 0.010 |
Why?
|
Graft Rejection | 1 | 1997 | 4446 | 0.010 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2006 | 717 | 0.010 |
Why?
|
Ovarian Neoplasms | 1 | 2000 | 4849 | 0.010 |
Why?
|
Vaccines, Conjugate | 1 | 2005 | 328 | 0.010 |
Why?
|
Catheterization | 2 | 2003 | 1428 | 0.010 |
Why?
|
Physician's Role | 1 | 2010 | 917 | 0.010 |
Why?
|
Pain | 2 | 2010 | 5061 | 0.010 |
Why?
|
Biopsy, Needle | 1 | 2007 | 1624 | 0.010 |
Why?
|
Virulence Factors | 1 | 1986 | 513 | 0.010 |
Why?
|
Thiotepa | 1 | 2002 | 66 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 2010 | 2382 | 0.010 |
Why?
|
Transforming Growth Factor beta | 1 | 2009 | 1963 | 0.010 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily B | 1 | 2001 | 84 | 0.010 |
Why?
|
Life Tables | 1 | 2002 | 364 | 0.010 |
Why?
|
Graft Survival | 1 | 2012 | 3820 | 0.010 |
Why?
|
NF-kappa B | 1 | 2010 | 2481 | 0.010 |
Why?
|
Plasmacytoma | 1 | 2002 | 171 | 0.010 |
Why?
|
Child, Preschool | 4 | 2010 | 42188 | 0.010 |
Why?
|
Macrophages | 1 | 1996 | 5758 | 0.010 |
Why?
|
Cell Line | 2 | 2008 | 15576 | 0.010 |
Why?
|
Neoplasm Metastasis | 2 | 2002 | 4910 | 0.010 |
Why?
|
Blood Cells | 1 | 2003 | 305 | 0.010 |
Why?
|
Immunization Schedule | 1 | 2002 | 227 | 0.010 |
Why?
|
Risk Factors | 3 | 2019 | 74115 | 0.010 |
Why?
|
Immunization | 1 | 2005 | 1217 | 0.010 |
Why?
|
Bacterial Toxins | 1 | 1986 | 925 | 0.010 |
Why?
|
Bilirubin | 1 | 2002 | 435 | 0.010 |
Why?
|
Microtubules | 1 | 2006 | 1073 | 0.010 |
Why?
|
Lung Neoplasms | 2 | 2017 | 13382 | 0.010 |
Why?
|
Ascites | 1 | 2002 | 338 | 0.010 |
Why?
|
Pneumococcal Infections | 1 | 2005 | 501 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2015 | 11116 | 0.010 |
Why?
|
Prevalence | 1 | 2017 | 15689 | 0.010 |
Why?
|
Regeneration | 1 | 2008 | 1505 | 0.010 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2002 | 410 | 0.010 |
Why?
|
Mitochondria | 1 | 2012 | 3619 | 0.010 |
Why?
|
Antibodies, Bacterial | 1 | 2005 | 1463 | 0.010 |
Why?
|
Carboplatin | 1 | 2002 | 793 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2015 | 6483 | 0.010 |
Why?
|
Pseudomonas aeruginosa | 1 | 1986 | 1272 | 0.010 |
Why?
|
Aging | 1 | 1997 | 8699 | 0.010 |
Why?
|
Immunologic Memory | 1 | 2005 | 1355 | 0.010 |
Why?
|
Cell Adhesion | 1 | 2004 | 3088 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2012 | 12334 | 0.010 |
Why?
|
Infant | 3 | 2010 | 36152 | 0.010 |
Why?
|
Infusions, Intravenous | 1 | 2002 | 2214 | 0.010 |
Why?
|
Progesterone | 1 | 2002 | 742 | 0.010 |
Why?
|
Antigens, Surface | 1 | 2001 | 1605 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 2004 | 2639 | 0.010 |
Why?
|
Fluorouracil | 1 | 2002 | 1642 | 0.010 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2000 | 825 | 0.010 |
Why?
|
Child | 4 | 2010 | 80079 | 0.010 |
Why?
|
Cyclophosphamide | 1 | 2002 | 2218 | 0.010 |
Why?
|
Stem Cell Factor | 1 | 1996 | 195 | 0.010 |
Why?
|
HeLa Cells | 1 | 2001 | 3087 | 0.010 |
Why?
|
Estrogens | 1 | 2002 | 1521 | 0.010 |
Why?
|
Disease Progression | 1 | 2011 | 13495 | 0.010 |
Why?
|
Incidence | 1 | 2011 | 21337 | 0.010 |
Why?
|
DNA, Viral | 1 | 1999 | 2195 | 0.010 |
Why?
|
Biopsy | 1 | 2002 | 6762 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2010 | 26180 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2002 | 12043 | 0.000 |
Why?
|
Proportional Hazards Models | 1 | 2002 | 12447 | 0.000 |
Why?
|
Liver | 1 | 2002 | 7512 | 0.000 |
Why?
|
HIV Infections | 1 | 2012 | 17337 | 0.000 |
Why?
|
Neutralization Tests | 1 | 1986 | 725 | 0.000 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 1986 | 426 | 0.000 |
Why?
|
Pulmonary Artery | 1 | 1993 | 1927 | 0.000 |
Why?
|
Antibody Specificity | 1 | 1986 | 1058 | 0.000 |
Why?
|
Nucleotidyltransferases | 1 | 1986 | 244 | 0.000 |
Why?
|
Epitopes | 1 | 1986 | 2501 | 0.000 |
Why?
|